OPDIVO 10 mg/mL concentrate for solution for infusion. clinical trials
50 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Phase II Study of BMS-986315 and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-line Treatment for Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer. It combines standard chemotherapy with two different drug approaches to see which works best and if there are side effects. Doctors want to find better treatments for non-small cell lung cancer.
For: Non-small Cell Lung CancerSpain · Romania · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
This study looks at a new combination treatment for advanced melanoma that has been removed by surgery. It compares two drugs given together (nivolumab and relatlimab) against nivolumab alone, to see if the combination can help prevent the cancer from coming back.
For: Participants with completely resected Stage III or Stage IV melanomaCzechia · Denmark · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
This study is testing if adding two new drugs, nivolumab and ipilimumab, to standard chemotherapy works better than chemotherapy alone for advanced lung cancer. It seeks to understand if this new combination helps people live longer.
For: Stage IV Non-Small Cell Lung Cancer (NSCLC)Spain · Ireland · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
This study is looking at new ways to treat bladder cancer that has spread or can't be removed with surgery. It compares a new combination of medicines with standard chemotherapy to see which works best at helping people live longer. Participants will be randomly assigned to different treatment groups.
For: Untreated Unresectable or Metastatic Urothelial CancerGermany · Greece · Denmark - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
This study is testing a new medicine, BMS-986253, alongside existing cancer treatments (Nivolumab and Ipilimumab) for advanced cancers. Doctors want to see how safe the combined medicines are and if they help shrink tumors. It's an early-stage study to gather important information.
For: Advanced solid tumorsItaly · Germany · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First-In-Human, Multi-Part, Open Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
This study is testing a new drug (DF6002) for advanced cancers, alone or with an existing drug (Nivolumab). It's looking to see if it's safe, how it moves through the body, and if it helps shrink tumors. It's an early-stage trial for people with solid tumors.
For: Advanced Solid TumorsFrance · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)
This study is testing new combinations of medicines for advanced liver cancer. We want to see if these treatments are safe and how well they shrink cancer or stop it from growing. It will involve different groups of patients trying different treatment plans.
For: Advanced/metastatic hepatocellular carcinoma (HCC)Germany · Spain · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS- 986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
This study is looking at new ways to treat bladder cancer that has grown into the muscle. It compares standard chemotherapy with chemotherapy plus new immunotherapy drugs (like Nivolumab) before and after surgery, to see which approach works best and is safest.
For: Bladder Cancer Muscle-Invasive Bladder CancerGermany · Norway · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
This study is looking at a new treatment combination for a type of lung cancer called extensive-stage small cell lung cancer. It combines an approved drug (Nivolumab, also known as OPDIVO) with two standard chemotherapy drugs and a new study drug, BMS-986012, to see if it helps patients.
For: Extensive-stage Small Cell Lung CancerRomania · Spain · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
This study looks at a new way to treat advanced lung cancer. It compares continuing a combination of two immunotherapy drugs (Nivolumab and Ipilimumab) after initial treatment with simply watching to see what happens. The goal is to find out which approach works better at keeping the cancer from growing.
For: Non small cell lung cancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)
This study looks at new drug combinations before surgery for early-stage lung cancer. We want to find the best ways to use these treatments to help patients prepare for surgery and to understand how they work with the body's immune system.
For: non-small cell lung cancer (NSCLC) of clinical stages IB · II and selected stage III ANetherlands · Germany · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer (SOGUG-VEXILLUM)
This study is looking at two medicines, nivolumab and ipilimumab, for people with advanced bladder cancer that can’t be removed by surgery. It wants to see if these medicines can help keep the cancer from growing after initial chemotherapy.
For: Unresectable locally advanced or metastatic urothelial cancerSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
This study is testing two new medicines, YERVOY and OPDIVO, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see how well they control the cancer and if they cause any side effects.
For: castration-resistant prostate cancerNetherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
This study is looking at treatments for different advanced cancers like breast, stomach, and lung cancer. It’s testing a new medicine called nivolumab, alone or with another drug, ipilimumab, to see how well they shrink tumors and if they have side effects.
Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)
This study is looking at new ways to treat a type of lung cancer that hasn't spread widely. It compares standard treatments with new drug combinations to see if they can stop the cancer from growing for longer. It aims to find the best treatment for patients with this type of lung cancer.
For: Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)France · Netherlands · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
This study looks at new ways to treat early-stage lung cancer. It compares standard chemotherapy with treatments that combine chemotherapy with new medicines called nivolumab and ipilimumab, to see if they work better at stopping the cancer from returning.
For: Early Stage Non-Small Cell Lung Cancer (NSCLC)France · Italy · Romania - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
This study is testing a new drug, BMS-986408, alone and with existing cancer drugs, nivolumab and ipilimumab, for advanced solid tumours. It aims to see how safe the new drug is and what side effects it might cause, as well as how well it works.
For: Advanced Solid TumoursFrance · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
This study is looking at a new combination of two medicines, nivolumab and relatlimab, for adults with advanced liver cancer that has progressed despite previous treatments. It aims to see how well this new combination shrinks tumors and if it's safe.
For: Advanced Hepatocellular CarcinomaRomania · Poland · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
This study is looking at a new way to give nivolumab, a cancer medicine, through an injection under the skin. It's for people with various advanced cancers like lung, kidney, and liver cancer, to see how the body handles the medicine and if it's safe.
For: lung cancer · kidney cancer · melanomaSpain · Netherlands · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer
This study is looking into a new drug, BMS-986442, for people with advanced solid tumours, including a type of lung cancer. It combines this new drug with existing cancer medicines to see if it's safe and helps shrink tumours. Researchers are checking for side effects and how well the treatments work.
For: Solid Tumor · Non-small cell lung cancerSpain · Italy · Poland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma
This study is testing a new medicine called SOT102 for stomach and pancreatic cancer. Researchers want to find the safest dose of SOT102, both alone and with standard treatments, and see if it helps shrink tumours. It's an early-stage study, open to adults.
For: gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinomaSpain · Czechia · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
This study looks at new drug combinations for men with advanced prostate cancer that has stopped responding to hormone therapy. It compares different treatments to see which works best at shrinking tumours and slowing cancer growth.
For: Metastatic Castration-Resistant Prostate CancerGermany - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
This study is looking at new treatments, relatlimab and nivolumab, for young people (up to 18 years old) with types of blood cancer called Hodgkin Lymphoma and Non-Hodgkin Lymphoma. It checks if they are safe and if they help shrink the cancer when other treatments haven't worked.
For: Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin LymphomaNetherlands · Spain · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It compares a combination of two new medicines (Nivolumab and Ipilimumab) with a standard medicine (Sunitinib) to see which works better at helping people live longer and stopping the cancer from growing.
For: Advanced or metastatic renal cell carcinomaGermany · Ireland · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INTEGRATE IIb A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
This study is testing two medicines, regorafenib and nivolumab, against standard chemotherapy for advanced stomach or gullet cancer that hasn't responded to previous treatments. Researchers want to see if this new combination helps people live longer.
For: refractory · advanced gastro-oesophageal cancerAustria · Germany · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
This study looks at new ways to treat Hodgkin lymphoma, a type of cancer that affects the immune system. Researchers are testing different combinations of medicines to see how well they work and if they are safe. The main goal is to see if these treatments can make the cancer go away completely.
For: Classical Hodgkin LymphomaSpain · Czechia · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
This study is testing a new medicine, BMS-986288, alone and with another drug, nivolumab. It's for people with various advanced cancers. The main goals are to check for side effects and how well the new medicine works against the cancer.
For: Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN) · non-small cell lung cancer (NSCLC) · cutaneous melanomaSpain · France · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
This study is looking at a new treatment for advanced cancers. We're testing a new drug, BMS-986016, alone and with an existing cancer drug, Nivolumab, to see how safe and effective they are. It's a key first step in understanding these potential new treatments.
For: Neoplasms by siteFinland · Norway · Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
This study looks at whether a drug called Nivolumab can help prevent cancer from coming back in people who have had surgery for oesophageal or stomach cancer. It compares Nivolumab to a dummy drug to see if it improves the time patients live without their cancer returning.
For: Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancerBelgium · Spain · Romania - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
This study looks at new ways to treat advanced cancers using a combination of different medications. Researchers want to see how safe these combinations are and how well they work to shrink tumours or stop them from growing.
For: Advanced Malignant TumorsItaly · France · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
For: Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)Austria · Italy · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new treatments for advanced kidney cancer. It compares a combination of two drugs, nivolumab and cabozantinib, against a standard treatment, sunitinib, to see which works better and is safer for people who haven't had treatment before.
For: Advanced or Metastatic Renal Cell CarcinomaPoland · Spain · Czechia - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with metastatic or recurrent melanoma
This study is looking at a new treatment called ATL001 for advanced melanoma, a serious skin cancer. It aims to see how safe the treatment is and if it helps by checking for side effects and changes in tumour size.
For: Metastatic or recurrent melanomaSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemo-therapy alone for the treatment of locally advanced and potentially resectable non-small cell lung cancer (NSCLC) patients_NADIM II
This study looks at a new way to treat certain lung cancers before surgery. It compares whether adding an immunotherapy drug called OPDIVO to standard chemotherapy works better than chemotherapy alone for advanced non-small cell lung cancer.
For: Non-small cell lung cancer (NSCLC)Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS
This study looks at how long immunotherapy works for people with advanced lung cancer and how it affects their bodies. We're testing different drug combinations to see which works best and for how long, to improve treatment plans.
For: Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.France - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A global multicenter phase 1/2 trial of EO4010, a novel microbial-derived peptide therapeutic vaccine, in combination with nivolumab and/or bevacizumab, for treatment of patients with previously treated metastatic colorectal carcinoma (the "AUDREY" study).
This study, called "AUDREY," is for people with bowel cancer that has spread and has been treated before. It tests a new vaccine called EO4010 with existing cancer medicines to see if it's safe and helps improve treatment.
For: Patients with unresectable · previously treated locally advanced or metastatic colorectal carcinoma.France · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers
This study looks at new ways to treat early-stage triple-negative breast cancer. It tests a drug called nivolumab alongside standard chemotherapy to see if it helps shrink tumours more effectively before surgery. The aim is to improve treatment results for this type of breast cancer.
For: Early stage triple negative breast cancerItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy
This study compares two ways of giving a medicine called Nivolumab for advanced kidney cancer. One way is an injection under the skin, and the other is a drip into a vein. Doctors want to see if the injection works just as well and is safe for patients.
For: Metastatic Clear Cell Renal Cell CarcinomaItaly · Spain · Finland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
This study is testing a new combination of medicines, Sitravatinib and Nivolumab, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It's for people whose cancer has grown after previous chemotherapy and immunotherapy.
For: Advanced Non-Squamous Non-Small Cell Lung CancerSpain · Netherlands · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZED PHASE II STUDY
This study is looking at two new drug combinations for adults with advanced soft-tissue sarcoma. It aims to see if a combination of nivolumab and relatlimab, or nivolumab alone, can help control the cancer for at least six months. The trial is in its early stages.
For: Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.France - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
This study is testing a new treatment called RP1, by itself and with another medicine (Opdivo), for adults with various types of cancer (solid tumors). It aims to see how safe the treatment is and if it helps shrink tumors.
For: Solid tumorsGermany · France · Spain - Ongoing, recruitingPhase II and Phase III (Integrated)
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study
This study looks at a new drug called nivolumab for people with oesophageal cancer who have had previous treatment. It aims to see if nivolumab can help stop the cancer from coming back after surgery and chemotherapy/radiotherapy, by carefully monitoring patients for any return of the disease.
For: oesophageal cancerNetherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer
This study looks at new drug combinations for advanced bowel cancer. It's for people whose cancer has grown or spread, and aims to see how well these new treatments shrink tumours, using drugs that boost the body's own immune system.
For: MSI Negative Colorectal Cancer · MSI Positive Colorectal CancerBelgium · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refractory Acute Myeloid Leukemia and in Combination with 5-Azacytidine and Venetoclax for Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Negative for NPM1 and IDH 1/2 Mutations Who Are Ineligible for Intensive Chemotherapy (AARON)
This study looks at new drug combinations for acute myeloid leukaemia (AML). It aims to find the safest dose and see how well these combinations work in people whose AML has come back or not responded to treatment, and in newly diagnosed patients who can't have strong chemotherapy.
For: Acute Myeloid LeukemiaGermany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS
This study is testing a new treatment called Oncobax®-AK, given alongside established immunotherapy drugs, for people with advanced lung or kidney cancer. It's looking for the safest dose and early signs of how well it works. This is an early-stage trial, focusing on safety.
For: Non-Small Cell Lung Cancer (NSCLC) · Renal Cell Carcinoma (RCC)Belgium · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
This study is for people with kidney cancer that has grown or come back after previous treatments. It compares a new combination of two drugs, tivozanib and nivolumab, against tivozanib on its own. The aim is to see if the combination helps people live longer without their cancer growing.
For: Renal cell carcinomaItaly · Germany · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor Treatment - The FRACTION Trial
This study looks at combining two medicines, fedratinib and nivolumab, for people with myelofibrosis whose current JAK-inhibitor treatment isn't working well. We want to see how well this new combination reduces symptoms and if people need fewer blood transfusions.
For: Primary and secondary MyelofibrosisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
This study is testing different medicines for people with advanced kidney cancer (non-clear cell renal carcinoma) that has spread. It's looking for personalised treatments to see which ones shrink the cancer and how long they keep it under control. The goal is to find better ways to treat this type of cancer.
For: Metastatic non-clear cell renal cell carcinomaDenmark - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
This study is testing a new treatment, DF1001, for advanced or spreading cancers. It will look at how safe the treatment is, what side effects it causes, and how it affects the body. Researchers also want to see if it can help shrink tumours or stop them from growing.
For: Locally Advanced or Metastatic Solid Tumors · and Expansion in Selected IndicationsDenmark · Netherlands · Belgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors
This study is testing a new drug called BDC-1001, both on its own and with another medicine called Nivolumab. It's for adults with advanced cancers that have a specific marker called HER2. The main goal is to see if these treatments are safe and what side effects they might cause.
For: Advanced HER2-Expressing Solid Tumors.France